West nile virus vaccine comprising WN-80E recombinant subunit protein
US10039820B2 · kind B2 · utility
16Cited by
3References
7Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Oct 21, 2016 |
| Grant date | Aug 7, 2018 |
| Priority date | — |
| Expiry date | Oct 21, 2036 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY02A50/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A West Nile virus vaccine for human use is described that preferably contains a recombinantly produced form of truncated West Nile virus envelope glycoprotein and aluminum adjuvant. The vaccine is acceptable for use in the general population, including immunosuppressed, immunocompromised, and immunosenescent individuals. The vaccine is safe and effective for use in all healthy and at-risk populations. A pharmaceutically acceptable vehicle may also be included in the vaccine.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.